Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504488 · ClinicalTrials.gov registry record · Phase 1
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
A Phase 1 study, sponsored by BioAtla.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT03504488 is a Phase 1 study that has completed, run by BioAtla. The registered enrollment target is 132 participants.
The verdict
NCT03504488, a Phase 1 study, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-ROR2-ADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03504488
The ClinicalTrials.gov registry entry for NCT03504488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioAtla, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PD-1 inhibitor is the first listed.
NCT03504488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03504488 about?
NCT03504488 is a clinical study titled "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)". The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
What is the current status of trial NCT03504488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2018-06-27. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT03504488?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-ROR2-ADC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03504488?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.